A DOUBLE-BLIND COMPARATIVE MULTICENTER STUDY OF CONTROLLED-RELEASE REMOXIPRIDE, IMMEDIATE-RELEASE REMOXIPRIDE AND HALOPERIDOL IN SCHIZOPHRENIA

被引:9
作者
HEBENSTREIT, GF
LAUX, G
SCHUBERT, H
BECKMANN, H
AMMAN, J
BUNSE, J
EIKMEIER, G
GERETSEGGER, C
KANITZ, RD
KANZOW, WT
KONIG, P
MAIR, M
MAYR, H
PLATZ, T
RITTMANNSBERGER, H
SCHONY, HW
STRUCK, M
VISKIHANKA, Z
WIBMER, M
ZOCHLING, R
机构
[1] PSYCHIAT STATE HOSP MAUER,MAUER,AUSTRIA
[2] PSYCHIAT STATE HOSP HALL,HALL,AUSTRIA
[3] UNIV WURZBURG,DEPT PSYCHIAT,W-8700 WURZBURG,GERMANY
[4] PSYCHIAT STATE HOSP VALDUNA,RANKWEIL,AUSTRIA
[5] RHENISH STATE & UNIV CLIN,ESSEN,GERMANY
[6] UNIV BOCHUM,DEPT PSYCHIAT,GELSENKIRCHEN,GERMANY
[7] PSYCHIAT HOSP MARBURG,MARBURG,GERMANY
[8] PSYCHIAT STATE HOSP SALZBURG,SALZBURG,AUSTRIA
[9] WAGNER JAUREGG KRANKENHAUSE,LINZ,AUSTRIA
[10] PSYCHIAT STATE HOSP KLAGENFURT,KLAGENFURT,AUSTRIA
[11] PSYCHIAT STATE HOSP GRAZ,GRAZ,AUSTRIA
关键词
D O I
10.1055/s-2007-1014460
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A double-blind multicentre study comparing the efficacy and safety of remoxipride in controlled-release formulation (REM-CR), given once a day, and immediate-release formulation (REM-IR) and haloperidol, given twice daily, was conducted in patients with schizophrenic illness. In total, 150 inpatients were randomized: 49, 51 and 50 in the REM-CR, REM-IR, and haloperidol groups, respectively. - The mean daily dose of REM-CR during the last week of treatment was 361 mg, that of REM-IR 332 mg. In the haloperidol group the corresponding dose was 12.5 mg per day. The study treatment period was four weeks. - The median BPRS total score was 37.5 in the REM-CR group at start of treatment, and 14.5 at last rating (n = 38). For the REM-IR group and the haloperidol group the corresponding figures were 36.0 and 38.0 at start of treatment and 18.0 (n = 43) and 16.5 (n = 40) at last rating. No statistically significant differences were found between the treatments. - Therapy-emergent extrapyramidal symptoms (Simpson & Angus rating scale) were significantly (p < 0.05) more frequent and more severe during haloperidol than during REM-CR and REM-IR treatment, despite significantly higher concurrent use of anticholinergic drugs in the haloperidol group. - REM-CR was comparable in efficacy and tolerability to REM-IR. The tolerability profile favoured both remoxipride formulations over haloperidol. Evaluation of the clinical chemistry, haematology, and cardiovascular data showed no clinically significant deleterious effects on any organ system for either drug.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 11 条
  • [1] Everitt Brian, 1977, ANAL CONTINGENCY TAB
  • [2] Lehman EL, 1975, NONPARAMETRICS STATI, P204
  • [3] LEWANDER R, 1990, ACTA PSYCHIATR S358, V90, P92
  • [4] DETERMINATION OF REMOXIPRIDE IN PLASMA AND URINE BY REVERSED-PHASE COLUMN LIQUID-CHROMATOGRAPHY
    NILSSON, LB
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 526 (01): : 139 - 150
  • [5] REMOXIPRIDE, A NEW POTENTIAL ANTIPSYCHOTIC COMPOUND WITH SELECTIVE ANTIDOPAMINERGIC ACTIONS IN THE RAT-BRAIN
    OGREN, SO
    HALL, H
    KOHLER, C
    MAGNUSSON, O
    LINDBOM, LO
    ANGEBY, K
    FLORVALL, L
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 102 (3-4) : 459 - 474
  • [6] NEUROPHARMACOLOGICAL AND BEHAVIORAL PROPERTIES OF REMOXIPRIDE IN THE RAT
    OGREN, SO
    FLORVALL, L
    HALL, H
    MAGNUSSON, O
    ANGEBYMOLLER, K
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1990, 82 : 21 - 26
  • [7] PFLUG B, 1990, ACTA PSYCHIATR S358, V90, P142
  • [8] Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11
  • [9] STEADY-STATE PHARMACOKINETICS OF CONTROLLED RELEASE AND IMMEDIATE RELEASE FORMULATIONS OF REMOXIPRIDE IN PATIENTS WITH CHRONIC-SCHIZOPHRENIA
    TENCH, D
    SONI, SD
    ASHWOOD, T
    MOVIN, G
    [J]. PSYCHOPHARMACOLOGY, 1990, 101 (01) : 132 - 136
  • [10] 1986, INT SKALEN PSYCHIATR